Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial

BACKGROUND: Cabazitaxel is a novel taxane that might be active in breast cancer resistant to first-generation taxanes. METHODS: The purpose of the current multicentre phase II trial was to evaluate the activity and safety of cabazitaxel, as second-line treatment, in patients with human epidermal gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Koutras, Angelos, Zagouri, Flora, Koliou, Georgia-Angeliki, Psoma, Elizabeth, Chryssogonidis, Ioannis, Lazaridis, Georgios, Tryfonopoulos, Dimitrios, Kotsakis, Athanasios, Res, Eleni, Kentepozidis, Nikolaos K., Razis, Evangelia, Psyrri, Amanda, Koumakis, Georgios, Kalofonos, Haralabos P., Dimopoulos, Meletios A., Fountzilas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403584/
https://www.ncbi.nlm.nih.gov/pubmed/32488135
http://dx.doi.org/10.1038/s41416-020-0909-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403584/
https://www.ncbi.nlm.nih.gov/pubmed/32488135
http://dx.doi.org/10.1038/s41416-020-0909-4

Ejemplares similares